Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anastasios Raptis

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Haematologica|August 8, 2024
A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemiaKevin Quann, Konstantinos Lontos, Alison Sehgal, et al.
Cytotherapy|September 3, 2017
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemiaMichael Boyiadzis, Mounzer Agha, Robert L Redner, et al.
Cancer Research|August 7, 2012
The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical careLinda Bosserman, Franklyn Prendergast, Roy Herbst, et al.
British Journal of Haematology|October 21, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON studyAlessandra Larocca, Xavier Leleu, Cyrille Touzeau, et al.
Open Forum Infectious Diseases|June 2, 2023
Rapid Emergence of Potentially Transmissible Severe Acute Respiratory Syndrome Coronavirus 2 With Resistance to Combination Monoclonal Antibody TherapyJana L Jacobs, Ghady Haidar, Asma Naqvi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2020
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple MyelomaPaul G Richardson, Albert Oriol, Alessandra Larocca, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 20, 2023
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised PatientsGhady Haidar, Jana L Jacobs, Kailey Hughes Kramer, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Haematologica|August 8, 2024
A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemiaKevin Quann, Konstantinos Lontos, Alison Sehgal, et al.
Cytotherapy|September 3, 2017
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemiaMichael Boyiadzis, Mounzer Agha, Robert L Redner, et al.
Cancer Research|August 7, 2012
The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical careLinda Bosserman, Franklyn Prendergast, Roy Herbst, et al.
British Journal of Haematology|October 21, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON studyAlessandra Larocca, Xavier Leleu, Cyrille Touzeau, et al.
Open Forum Infectious Diseases|June 2, 2023
Rapid Emergence of Potentially Transmissible Severe Acute Respiratory Syndrome Coronavirus 2 With Resistance to Combination Monoclonal Antibody TherapyJana L Jacobs, Ghady Haidar, Asma Naqvi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2020
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple MyelomaPaul G Richardson, Albert Oriol, Alessandra Larocca, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 20, 2023
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised PatientsGhady Haidar, Jana L Jacobs, Kailey Hughes Kramer, et al.
Pageof 6